ABOS
Acumen Pharmaceuticals, Inc.
Biotechnology
Market Cap$150M
5Y Perf.-84.0%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
ABOS vs ATNM vs RCUS vs ARQT vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
ATNM
Actinium Pharmaceuticals, Inc.
Biotechnology
Market Cap$38M
5Y Perf.-81.7%
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.50B
5Y Perf.-21.1%
ARQT
Arcutis Biotherapeutics, Inc.
Biotechnology
Market Cap$2.58B
5Y Perf.-11.4%
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-89.1%
ABOS vs ATNM vs RCUS vs ARQT vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ABOS | ATNM | RCUS | ARQT | NVCR |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Medical - Instruments & Supplies |
| Market Cap | $150M | $38M | $2.50B | $2.58B | $1.92B |
| Revenue (TTM) | $0.00 | $90K | $236M | $416M | $674M |
| Net Income (TTM) | $-133M | $-35M | $-369M | $-2M | $-173M |
| Gross Margin | — | -8.1% | 90.7% | 90.9% | 75.2% |
| Operating Margin | — | -414.9% | -168.6% | 0.8% | -27.2% |
| Forward P/E | — | — | — | 77.6x | — |
| Total Debt | $30M | $2M | $99M | $6M | $290M |
| Cash & Equiv. | $36M | $73M | $222M | $43M | $103M |
ABOS vs ATNM vs RCUS vs ARQT vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ABOS
ATNM
RCUS
ARQT
NVCR
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Acumen Pharmaceutic… (ABOS) | 100 | 16.0 | -84.0% |
| Actinium Pharmaceut… (ATNM) | 100 | 18.3 | -81.7% |
| Arcus Biosciences, … (RCUS) | 100 | 78.9 | -21.1% |
| Arcutis Biotherapeu… (ARQT) | 100 | 88.6 | -11.4% |
| NovoCure Limited (NVCR) | 100 | 10.9 | -89.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ABOS vs ATNM vs RCUS vs ARQT vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ARQT leads in 2 of 6 categories (5-stock set), making it the strongest pick for growth and revenue expansion and operational efficiency and capital deployment. Acumen Pharmaceuticals, Inc. is the stronger pick specifically for profitability and margin quality. ATNM and RCUS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ABOS
Acumen Pharmaceuticals, Inc.
The Quality Compounder
ABOS is the #2 pick in this set and the best alternative if quality is your priority.
- 4.3% margin vs ATNM's -384.4%
Best for: quality
ATNM
Actinium Pharmaceuticals, Inc.
The Income Pick
ATNM ranks third and is worth considering specifically for income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.40
- Lower volatility, beta 1.40, Low D/E 4.8%, current ratio 9.14x
- Beta 1.40, current ratio 9.14x
- Beta 1.40 vs NVCR's 2.20, lower leverage
Best for: income & stability and sleep-well-at-night
RCUS
Arcus Biosciences, Inc.
The Long-Run Compounder
RCUS is the clearest fit if your priority is long-term compounding.
- 45.9% 10Y total return vs ARQT's -5.2%
- +209.6% vs ATNM's -12.9%
Best for: long-term compounding
ARQT
Arcutis Biotherapeutics, Inc.
The Growth Play
ARQT carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 91.3%, EPS growth 88.8%, 3Y rev CAGR 367.3%
- 91.3% revenue growth vs ATNM's -100.0%
- -0.6% ROA vs ABOS's -93.8%, ROIC -5.2% vs -42.3%
Best for: growth exposure
NVCR
NovoCure Limited
The Healthcare Pick
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARQT | 91.3% revenue growth vs ATNM's -100.0% |
| Quality / Margins | ABOS | 4.3% margin vs ATNM's -384.4% |
| Stability / Safety | ATNM | Beta 1.40 vs NVCR's 2.20, lower leverage |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | RCUS | +209.6% vs ATNM's -12.9% |
| Efficiency (ROA) | ARQT | -0.6% ROA vs ABOS's -93.8%, ROIC -5.2% vs -42.3% |
ABOS vs ATNM vs RCUS vs ARQT vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
FY 2025
FY 2023
Segment breakdown not available.
ABOS vs ATNM vs RCUS vs ARQT vs NVCR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARQTLAGGINGNVCR
Who Leads Where
ARQT leads in 2 of 6 categories
RCUS leads 1 • ABOS leads 0 • ATNM leads 0 • NVCR leads 0 • 2 tied
Explore the data ↓NVCRNovoCure Limited
0leads
ATNMActinium Pharmaceutic…
0leads
ABOSAcumen Pharmaceutical…
0leads
RCUSArcus Biosciences, In…
1leads
ARQTArcutis Biotherapeuti…
2leads
6 Total Categories
CATEGORYLEADERvs RCUSvs ABOSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ARQT5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARQT6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
RCUS3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ARQT leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR and ABOS operate at a comparable scale, with $674M and $0 in trailing revenue. ARQT is the more profitable business, keeping -0.6% of every revenue dollar as net income compared to ATNM's -384.4%. On growth, ARQT holds the edge at +60.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ABOSAcumen Pharmaceut… | ATNMActinium Pharmace… | RCUSArcus Biosciences… | ARQTArcutis Biotherap… | NVCRNovoCure Limited |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $90,000 | $236M | $416M | $674M |
| EBITDAEarnings before interest/tax | -$137M | -$37M | -$391M | $6M | -$165M |
| Net IncomeAfter-tax profit | -$133M | -$35M | -$369M | -$2M | -$173M |
| Free Cash FlowCash after capex | -$124M | -$25M | -$489M | $27M | -$48M |
| Gross MarginGross profit ÷ Revenue | — | -8.1% | +90.7% | +90.9% | +75.2% |
| Operating MarginEBIT ÷ Revenue | — | -414.9% | -168.6% | +0.8% | -27.2% |
| Net MarginNet income ÷ Revenue | — | -384.4% | -156.4% | -0.6% | -25.7% |
| FCF MarginFCF ÷ Revenue | — | -278.2% | -2.1% | +6.5% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | -39.3% | +60.1% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +12.0% | +56.8% | +10.5% | +55.0% | -100.0% |
ARQT leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — ABOS and ARQT and NVCR each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | ABOSAcumen Pharmaceut… | ATNMActinium Pharmace… | RCUSArcus Biosciences… | ARQTArcutis Biotherap… | NVCRNovoCure Limited |
|---|---|---|---|---|---|
| Market CapShares × price | $150M | $38M | $2.5B | $2.6B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $144M | -$33M | $2.4B | $2.5B | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.44x | -0.96x | -7.54x | -158.92x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 77.64x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | 10.11x | 6.87x | 2.92x |
| Price / BookPrice ÷ Book value/share | 0.82x | 1.12x | 4.22x | 13.87x | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Evenly matched — ABOS and ARQT and NVCR each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ARQT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ARQT delivers a -1.4% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-152 for ATNM. ARQT carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), NVCR scores 5/9 vs RCUS's 0/9, reflecting solid financial health.
| Metric | ABOSAcumen Pharmaceut… | ATNMActinium Pharmace… | RCUSArcus Biosciences… | ARQTArcutis Biotherap… | NVCRNovoCure Limited |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -143.1% | -151.7% | -69.0% | -1.4% | -50.8% |
| ROA (TTM)Return on assets | -93.8% | -52.3% | -35.3% | -0.6% | -16.5% |
| ROICReturn on invested capital | -42.3% | — | -64.1% | -5.2% | -16.4% |
| ROCEReturn on capital employed | -44.8% | -59.5% | -42.1% | -4.3% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 | 0 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.16x | 0.05x | 0.16x | 0.03x | 0.85x |
| Net DebtTotal debt minus cash | -$6M | -$71M | -$123M | -$37M | $187M |
| Cash & Equiv.Liquid assets | $36M | $73M | $222M | $43M | $103M |
| Total DebtShort + long-term debt | $30M | $2M | $99M | $6M | $290M |
| Interest CoverageEBIT ÷ Interest expense | -30.95x | — | -13.38x | 2.08x | -96.80x |
ARQT leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
RCUS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RCUS five years ago would be worth $8,143 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, RCUS leads with a +209.6% total return vs ATNM's -12.9%. The 3-year compound annual growth rate (CAGR) favors ARQT at 13.2% vs ATNM's -47.9% — a key indicator of consistent wealth creation.
| Metric | ABOSAcumen Pharmaceut… | ATNMActinium Pharmace… | RCUSArcus Biosciences… | ARQTArcutis Biotherap… | NVCRNovoCure Limited |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +22.3% | -10.9% | +6.5% | -28.8% | +28.3% |
| 1-Year ReturnPast 12 months | +147.9% | -12.9% | +209.6% | +50.8% | +1.1% |
| 3-Year ReturnCumulative with dividends | -49.1% | -85.9% | +24.9% | +44.9% | -75.7% |
| 5-Year ReturnCumulative with dividends | -87.7% | -83.3% | -18.6% | -39.5% | -91.3% |
| 10-Year ReturnCumulative with dividends | -87.7% | -97.7% | +45.9% | -5.2% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -20.1% | -47.9% | +7.7% | +13.2% | -37.6% |
RCUS leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ATNM and RCUS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ATNM is the less volatile stock with a 1.40 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCUS currently trades 86.3% from its 52-week high vs ATNM's 62.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ABOSAcumen Pharmaceut… | ATNMActinium Pharmace… | RCUSArcus Biosciences… | ARQTArcutis Biotherap… | NVCRNovoCure Limited |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.93x | 1.40x | 1.95x | 1.48x | 2.20x |
| 52-Week HighHighest price in past year | $3.60 | $1.95 | $28.72 | $31.77 | $20.06 |
| 52-Week LowLowest price in past year | $0.96 | $0.95 | $7.06 | $12.42 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +68.6% | +62.6% | +86.3% | +65.0% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 49.0 | 52.8 | 60.5 | 54.3 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 595K | 184K | 1.2M | 1.3M | 1.5M |
Evenly matched — ATNM and RCUS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ABOS as "Buy", RCUS as "Buy", ARQT as "Buy", NVCR as "Buy". Consensus price targets imply 183.4% upside for ABOS (target: $7) vs 21.0% for RCUS (target: $30).
| Metric | ABOSAcumen Pharmaceut… | ATNMActinium Pharmace… | RCUSArcus Biosciences… | ARQTArcutis Biotherap… | NVCRNovoCure Limited |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $7.00 | — | $30.00 | $35.50 | $33.50 |
| # AnalystsCovering analysts | 7 | — | 18 | 12 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARQT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RCUS leads in 1 (Total Returns). 2 tied.
Best OverallArcutis Biotherapeutics, In… (ARQT)Leads 2 of 6 categories
Loading custom metrics...
ABOS vs ATNM vs RCUS vs ARQT vs NVCR: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ABOS or ATNM or RCUS or ARQT or NVCR a better buy right now?
For growth investors, Arcutis Biotherapeutics, Inc.
(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). Analysts rate Acumen Pharmaceuticals, Inc. (ABOS) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ABOS or ATNM or RCUS or ARQT or NVCR?
Over the past 5 years, Arcus Biosciences, Inc.
(RCUS) delivered a total return of -18. 6%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: RCUS returned +45. 9% versus ATNM's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ABOS or ATNM or RCUS or ARQT or NVCR?
By beta (market sensitivity over 5 years), Actinium Pharmaceuticals, Inc.
(ATNM) is the lower-risk stock at 1. 40β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 58% more volatile than ATNM relative to the S&P 500. On balance sheet safety, Arcutis Biotherapeutics, Inc. (ARQT) carries a lower debt/equity ratio of 3% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — ABOS or ATNM or RCUS or ARQT or NVCR?
By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.
(ARQT) is pulling ahead at 91. 3% versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -58. 3% for Acumen Pharmaceuticals, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ABOS or ATNM or RCUS or ARQT or NVCR?
Acumen Pharmaceuticals, Inc.
(ABOS) is the more profitable company, earning 0. 0% net margin versus -384. 4% for Actinium Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABOS leads at 0. 0% versus -414. 9% for ATNM. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ABOS or ATNM or RCUS or ARQT or NVCR more undervalued right now?
Analyst consensus price targets imply the most upside for ABOS: 183.
4% to $7. 00.
07Which pays a better dividend — ABOS or ATNM or RCUS or ARQT or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ABOS or ATNM or RCUS or ARQT or NVCR better for a retirement portfolio?
For long-horizon retirement investors, Actinium Pharmaceuticals, Inc.
(ATNM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Acumen Pharmaceuticals, Inc. (ABOS) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATNM: -97. 7%, ABOS: -87. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ABOS and ATNM and RCUS and ARQT and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ABOS is a small-cap quality compounder stock; ATNM is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.